|Bid||165.89 x 100|
|Ask||172.45 x 100|
|Day's Range||168.60 - 172.42|
|52 Week Range||88.90 - 178.15|
|PE Ratio (TTM)||163.95|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
PRA Health Sciences, just voted the Best CRO in Asia, may soon put its new buy point on trial.
The only "problem" mentioned by Vertex CEO Jeff Leiden? It's accumulating cash rapidly.
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith live from the floor of the New York Stock Exchange to discuss the latest market moves.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.